title: The effect of desacetyluvaricin on the expression of TLR4 and P53 protein in Hepg 2.2.15.
abstract: BACKGROUND
  Previous studies suggest that annonaceous may cause permeability glycoprotein (P-gp) function to abate, leading to cell apoptosis. It has also been reported that annonaceous acetogenins affect hepatocellular carcinoma (HCC) cells in the G1 phase, leading to apoptosis. Desacetyluvaricin (Des), a new type of annonaceous acetogenin monomer, has a significant effect on HCC, with few side effects.
  
  
  OBJECTIVE
  To investigate the effect of Des on the expression of Toll-like receptor 4 (TLR4) and P53 protein in HCC.
  
  
  METHODS
  HCC HepG2.2.15 cell was cultured by routine method. HepG2.2.15 cells were divided into three groups: control group, treated with Des and DDP (cisplatin) which were examined by immunofluorescence flow cytometry for expression of TLR4 and P53.
  
  
  RESULTS
  TLR4 was expressed by more cells in the Des group than in the cisplatin or serum-only groups (71.94%, 42.64%, and 37.16%, respectively; Des vs.cisplatin: p < 0.05; Des vs. serum only: p < 0.05), with no difference between the cisplatin and serum-only groups (p > 0.05). P53 was expressed by more cells in the Des and cisplatin groups than in the serum-only group (32.6%, 31.5% and 3.3%, respectively; Des vs. serum only, p < 0.05; cisplatin vs. serum only, p < 0.05), with no difference between the Des and cisplatin groups (p > 0.05).
  
  
  CONCLUSIONS
  Des increases TLR4 and P53 expression in HCC cells. Improved immune recognition by the former effect and induction of apoptosis by the latter could be the mechanisms of Des's clinical effects on HCC.
authors.affiliation: Department of Gastroenterology, the People's Hospital of Heshan, Guangdong, China.
authors.forename: Hai Bin
authors.initials: HB
authors.lastname: He
authors.forename: Xian Lin
authors.initials: XL
authors.lastname: Wu
authors.forename: Bin
authors.initials: B
authors.lastname: Yu
authors.forename: Kang Li
authors.initials: KL
authors.lastname: Liu
authors.forename: Guang Xiong
authors.initials: GX
authors.lastname: Zhou
authors.forename: Guo Qiang
authors.initials: GQ
authors.lastname: Qian
authors.forename: Da Hong
authors.initials: da H
authors.lastname: Ju
authors.forename: Xiao Yin
authors.initials: XY
authors.lastname: Chen
references.citation: Eur J Biochem. 2000 May;267(9):2538-46
references.pmid: 10785373
references.citation: Zhonghua Yi Xue Za Zhi. 2000 Jul;80(7):499-502
references.pmid: 11798806
references.citation: Cancer Res. 1997 Nov 15;57(22):5137-42
references.pmid: 9371515
references.citation: Oncogene. 2000 Jan 20;19(3):468-71
references.pmid: 10656696
references.citation: Nat Immunol. 2004 Oct;5(10):987-95
references.pmid: 15454922
references.citation: Bioorg Med Chem Lett. 2007 Jun 15;17(12):3426-30
references.pmid: 17433671
references.citation: Yao Xue Xue Bao. 2002 Oct;37(10):818-20
references.pmid: 12567869
references.citation: Genes Dev. 1996 Oct 1;10(19):2438-51
references.pmid: 8843196
references.citation: Cytometry. 1991;12(5):438-44
references.pmid: 1935458
references.citation: J Natl Cancer Inst. 2005 Dec 7;97(23):1778-81
references.pmid: 16333033
references.citation: Biochem Pharmacol. 2003 Feb 1;65(3):319-27
references.pmid: 12527325
references.citation: Cancer Res. 1991 Aug 15;51(16):4279-86
references.pmid: 1868448